( HDAC Inhibitor MGCD0103 Demonstrates s...)Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors,Health

HDAC Inhibitor MGCD0103 Demonstrates substantial Response Rate in Two Clinical Trials

Clinical Data Presented on Pilot Pharmacokinetic Study of Oral Azacitidine

Exelixis Reports Comprehensive XL880 Phase I Data At ASCO

Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

Studies Investigating Vidaza in Alternate Dosing Schedules in MDS and in Combination with Valproic Acid for Solid Tumors Presented at the American Society of Clinical Oncology 43rd Annual Meeting

* In alternate dose trial, transfusion independence achieved for 65% to 80% of patients transfusion dependent at baseline

CHICAGO, Ill., June 2, 2007 - Pharmion Corporation (NASDAQ: PHRM) reported today the interim results of several Vidaza (azacitidine for injection) studies in the treatment of hematologic malignancies and advanced solid tumors. These data were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. (June 1-5, 2007). Pharmion's epigenetic anti-cancer products, which include Vidaza, MCGD0103 and oral Azacitidine, are being investigated in the treatment of hematologic malignancies and solid tumors and are the subject of poster and oral presentations at the Meeting.

"As we continue to evaluate alternative dosing and schedules for Vidaza in MDS, and its potential in solid tumors, we are increasingly impressed with the activity this drug has in multiple tumor types," said Patrick J. Mahaffy, president and CEO of Pharmion. "These studies will help provide us with insight not only into the continuing development of parenteral Vidaza, but, in particular, provide us direction for the development of oral azacitidine."

Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine
'"/>